Lv6
1800 积分 2022-10-25 加入
Structural and Physicochemical Features of Oral PROTACs
3天前
已完结
Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials
11天前
已完结
HDM1002 in Chinese Adults With Overweight/Obesity: A Randomized, Placebo‐Controlled, Ascending‐Dose Phase 1b Study
17天前
已完结
First‐in‐human study of HDM1002 , a GLP ‐1 receptor agonist: Safety, tolerability, pharmacokinetics and pharmacodynamics of escalating single oral doses in healthy volunteers
17天前
已完结
Development of a clinically viable MRGPRX4 inverse agonist for cholestatic itch treatment
26天前
已完结
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
1个月前
已完结
Safety, tolerability and efficacy of repeated intravenous infusions of KHK4083, a fully human anti-OX40 monoclonal antibody, in Japanese patients with moderate to severe atopic dermatitis
1个月前
已完结
Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trials
1个月前
已完结
Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trials
1个月前
已完结
An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study
1个月前
已完结
皖公网安备34019202002308
